Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an
María-Victoria Mateos1,2,3,4, Noemí Puig1,2,3
1University Hospital of Salamanca.
Abstract
No abstract available in PubMed .
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.6K
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.0K